替格瑞洛与氯吡格雷对STEMI患者血清尿酸及血小板反应性的影响
该研究纳入967例接受急诊PCI的STEMI患者,比较替格瑞洛与氯吡格雷对30天血清尿酸水平及血小板反应性的影响。结果显示替格瑞洛组30天血清尿酸水平及变化幅度均高于氯吡格雷组,替格瑞洛是尿酸升高的独立相关因素,但尿酸变化未影响血小板聚集率或高血小板反应性比例。
要点
- 替格瑞洛组30天血清尿酸水平及变化幅度显著高于氯吡格雷组。
- 替格瑞洛是30天血清尿酸升高的独立相关因素(OR=1.582)。
- 两组尿酸变化均未影响血小板聚集率或高血小板反应性比例。
核心结论
- 替格瑞洛使用与STEMI患者急诊PCI术后30天血清尿酸水平显著升高相关。
- 替格瑞洛或氯吡格雷治疗期间血清尿酸变化未增加高血小板反应性比例。
研究设计与样本
- 研究纳入2017年4月至2020年1月于阜外医院行急诊PCI存活出院的STEMI患者967例。
- 患者分为替格瑞洛组550例(56.9%)和氯吡格雷组417例(43.1%),年龄(59.4±12.1)岁,女性163例。
- 检测基线和术后30天血清尿酸和肌酐,采用光学透射比浊法测量血小板聚集率,多因素logistic回归分析尿酸升高的相关因素。
主要发现
- 替格瑞洛组30天血清尿酸水平(347.2±96.5)mmol/L高于氯吡格雷组(341.2±105.3)mmol/L,P=0.009。
- 替格瑞洛组尿酸变化量46.4(-2.4,88.1)mmol/L高于氯吡格雷组25.0(-21.9,73.0)mmol/L,P=0.001;变化百分比13.2%(-0.01%,29.0%)高于7.9%(-5.7%,25.0)%,P=0.007。
- 替格瑞洛组30天血清肌酐(89.7±21.3)μmol/L低于氯吡格雷组(94.4±43.9)μmol/L,P<0.05;两组肌酐变化量和变化百分比差异无统计学意义(P均>0.05)。
关键数值与推荐
- 校正混杂因素后,替格瑞洛治疗是30天血清尿酸升高的独立相关因素(OR=1.582,95%CI:1.023-2.447,P=0.039)。
- 两组血清尿酸水平变化对血小板聚集率和血小板高反应性比例均无影响。
临床怎么用
- STEMI患者急诊PCI术后服用替格瑞洛者应关注30天血清尿酸水平变化。
- 替格瑞洛相关尿酸升高未伴随血小板高反应性增加,或可据此调整抗血小板治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objectives: To compare the impact of ticagrelor or clopidogrel on serum uric acid levels among patients with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) and further evaluate the effects of variation of serum uric acid levels on platelet reactivity. Methods: STEMI patients who admitted to Fuwai Hospital from April 2017 to January 2020, and underwent primary PCI and discharged alive with aspirin and ticagrelor or clopidogrel were included in this study. Patients were divided into ticagrelor group and clopidogrel group. The baseline clinical data were collected. Serum uric acid and creatinine levels at baseline and 30 days post-PCI were measured. Light transmittance aggregometry was used to assess maximum aggregation rate induced by adenosine diphosphate and arachidonic acid. The changes of serum uric acid and creatinine were compared between the two groups. Multivariate logistic regression was performed to evaluate independent related factors for rise in the uric acid levels, and the effect of variation of serum uric acid level on platelet reactivity was analyzed. Results: A total of 967 patients were included, the age was (59.4±12.1) years, and 163 case were female. There were 550 cases in ticagrelor group (56.9%) and 417 cases in clopidogrel group (43.1%). Baseline serum uric acid and creatinine levels were similar between the 2 groups. At 30 days, the serum uric acid level [(347.2±96.5) mmol/L vs. (341.2±105.3) mmol/L, P=0.009] and absolute [46.4 (-2.4, 88.1) mmol/L vs. 25.0 (-21.9, 73.0) mmol/L, P=0.001] and percentage [13.2 (-0.01, 29.0) % vs. 7.9 (-5.7, 25.0) %, P=0.007] increase in the serum uric acid levels were significantly higher in ticagrelor group than in clopidogrel group. The level of serum creatinine at 30 days was significantly lower in ticagrelor group than in clopidogrel group [(89.7±21.3) μmol/L vs. (94.4±43.9) μmol/L, P<0.05], whereas there were no differences in absolute [8.0 (-1.4, 16.6) μmol/L vs. 7.8 (-2.0, 16.6) μmol/L] and percentage [10.5 (-1.7%, 22.6%) vs. 9.8 (-2.4%, 22.1%)] change in the serum creatinine between the 2 groups (all P>0.05). Logistic regression analysis showed that, after adjusting for confounding factors, ticagrelor therapy was an independent related factor of serum uric acid elevation (OR=1.582, 95% CI:1.023-2.447, P=0.039). The variation of the serum uric acid levels did not affect platelet aggregation and the percentage of high platelet reactivity in both groups. Conclusions: Ticagrelor use is related to a significant increase in the serum uric acid levels at 30 days post-PCI in this patient cohort. The variations in the uric acid levels do not increase the percentage of high platelet reactivity in STEMI patients treated with ticagrelor or clopidogrel. 目的: 比较行急诊经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者在服用替格瑞洛和氯吡格雷期间血清尿酸水平的变化,并初步探讨血清尿酸水平的变化对血小板反应性的影响。 方法: 选取2017年4月至2020年1月于阜外医院行急诊PCI存活出院且接受阿司匹林和替格瑞洛或氯吡格雷治疗的STEMI患者,分为替格瑞洛组和氯吡格雷组。收集患者的基线临床资料,检测基线和术后30 d血清尿酸和肌酐水平,术后30 d采用光学透射比浊法测量二磷酸腺苷诱导和花生四烯酸诱导的最大聚集率。采用多因素logistic回归分析30 d时血清尿酸升高的独立相关因素,并分析血清尿酸水平对血小板反应性的影响。 结果: 共纳入患者967例,年龄(59.4±12.1)岁,女性163例(16.9%)。替格瑞洛组550例(56.9%),氯吡格雷组417例(43.1%)。2组基线血清尿酸和肌酐水平差异无统计学意义。替格瑞洛组30 d血清尿酸水平[(347.2±96.5)mmol/L比(341.2±105.3)mmol/L,P=0.009]、血清尿酸变化量[46.4(-2.4,88.1)mmol/L比25.0(-21.9,73.0)mmol/L,P=0.001]以及血清尿酸变化百分比[13.2%(-0.01%,29.0%)比7.9%(-5.7%,25.0%),P=0.007]均高于氯吡格雷组。替格瑞洛组30 d血清肌酐水平低于氯吡格雷组[(89.7±21.3)μmol/L比(94.4±43.9)μmol/L, P<0.05],但2组间血清肌酐变化量[8.0(-1.4,16.6)μmol/L比7.8(-2.0,16.6)μmol/L]和变化百分比[10.5%(-1.7%,22.6%)比9.8%(-2.4%,22.1%)]差异无统计学意义(P均>0.05)。logistic回归分析显示,校正混杂因素后,服用替格瑞洛是30 d血清尿酸升高的独立相关因素(OR=1.582,95% CI:1.023~2.447,P=0.039)。2组血清尿酸水平的变化对血小板聚集率和血小板高反应性均无影响。 结论: STEMI患者服用替格瑞洛30 d后血清尿酸水平升高,且增幅超过氯吡格雷服用者。初步研究显示,服用替格瑞洛和氯吡格雷期间,血清尿酸水平的升高没有增加血小板高反应性的比例。.
引用
- Song L, Xu DY, Zhou P, et al. [The variation of serum uric acid levels among patients with myocardial infarction treated with ticagrelor and the association between serum uric acid and platelet reactivity]. Zhonghua Xin Xue Guan Bing Za Zhi. 2021. PMID: 33611904. doi:10.3760/cma.j.cn112148-20200509-00383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。